参考文献 [1]FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. News release. FDA. July 30, 2024. Accessed July 30, 2024. https://tinyurl.com/ejvk4c3p [...
VRD方案治疗是一种针对多发性骨髓瘤(Multiple Myeloma,简称MM)的治疗方案。它是综合应用多种药物联合进行的治疗策略,能够有效控制疾病的进展,延长患者的生存期。VRD方案由小剂量地塞米松(Velcade)、利妥昔单抗(Revlimid)和地辛泼尼松(Dexamethasone)这三种药物组成。下面将详细介绍VRD方案治疗的原理、临床应用及其优点。
Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT. Subcutaneous Daratumumab Plus VRd Receives FDA Approval for Multiple Myeloma Daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved by the FDA in combinatio...
1.FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. FDA. September 20, 2024. Accessed September 20, 2024. https://www.fda.gov/drugs/resources-information-approv...
likely explore the integration of new modalities, such as bispecific antibodies, antibody-drug conjugates, and new cellular therapies, with this quadruplet regimen to further improve patient outcomes. The goal is to continue enhancing the efficacy and safety of treatments for multiple myeloma patients....
We retrospectively reviewed all patients (=243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55鈥 ...
on newly diagnosed transplant-ineligible multiple myeloma patients. The primary goal was to assess the clinical value of adding isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (bortezomib, lenalidomide, and dexamethasone), which is a well-established treatment for multiple myeloma. ...
参考来源:‘Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant’,新闻稿。Sanofi;2023年12月7日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治...
参考来源:‘Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant’,新闻稿。Sanofi;2023年12月7日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治...
参考文献 DuMontier C, et al.More intensive therapy as more effective treatment for frail patients with multiple myeloma.Blood Adv . 2023 Aug 15;bloodadvances.2023011019. doi: 10.1182/bloodadvances.2023011019. 授权转载、投稿等请联络梅...